• Huue

  Participated · Series A · Jul 2022

  Huue uses biotechnology to create sustainable, bio-based dyes that mirror how color is produced in nature. Its first product is a bio-based indigo dye for denim, designed to match conventional dyes in effectiveness without the environmental impact or toxic chemicals. Led by CEO and co-founder Michelle Zhu, the company is targeting fashion industry partners for commercial adoption. Huue plans to use new funding to accelerate commercial scale-up of its sustainable indigo dye and to expand beyond indigo to additional colors. The company also sees potential applications of its dye technology in food & beverage and personal care (cosmetics). Financially, Huue completed a $14.6M Series A to support its commercial expansion.

• Eclipse Bioinnovations

  Led · Series A · Mar 2022

  Eclipsebio is an RNA genomics company focused on developing technologies to enable effective development of RNA therapeutics. Led by CEO Peter Chu, the company offers end-to-end RNA genomics products as services and kits and provides custom RNA genomics services for select partners. The company intends to use new funding to expand its suite of RNA genomics technologies and products. Earlier in the year Eclipsebio relocated into an 18,000-square-foot corporate and research headquarters in Sorrento Valley, San Diego. In the new location it will expand its team of molecular biologists, bioinformatics scientists and its commercial group to support growth through increased awareness, education, and client-facing functions. The company also announced the appointment of Hallie Kuhn to its board; Daniel Vasella, M.D., and the cofounders serve as board members.

• The Pill Club

  Participated · Series B · Jun 2021

  The Pill Club operates an online platform that prescribes and delivers birth control through its own pharmacy, using a medical questionnaire and tele-nursing (live or text) to connect patients with options. Customers receive prescriptions and delivery to their door within two to three days. The company launched in 2016 and has expanded across most U.S. states, reaching 43 states plus D.C. by January 2021 and adding five more states since, with plans to reach all 50 states by the end of 2021. The Pill Club reported record revenues, crossing $100 million in annual run rate for the first time in its four-year history. It monetizes via medical visit fees, insurance reimbursement for prescriptions, and cash payments; 16% of new patients in the past three months were on Medicaid. The company is piloting additional services, including dermatology and expanded period care, and plans to use new capital to launch more services for members. The Pill Club operates a telemedicine and direct-to-consumer platform that prescribes and delivers birth control by combining healthcare services with at-home pharmacy fulfillment. The company runs its own pharmacy, is licensed to prescribe in 35 states, and reaches customers in all 50 states. It employs a team of doctors, nurses and patient care coordinators and has a roughly 260-person team. With the new financing the company plans to scale the business by 50% and expand its prescription service across the entire U.S. The Pill Club also intends to explore launching additional women’s-health services and broaden its educational content for customers. The company has raised $51M in a Series B, bringing total capital raised to $67M.

No current team members are available.